PPARA and metabolic dysfunction-associated steatotic liver disease: Considering that PPARα agonists fibrates, such as fenofibrates, have been widely used clinically to treat hyperlipidemia and, in some cases, NAFLD and NASH, it would be interestingly to further investigate whether fibrates also exert effects in the skeletal muscle.